- Home
- LGND vs HRMY Comparison
LGND vs HRMY Comparison
Compare LGND & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGND
- HRMY
- Stock Information
- Founded
- LGND 1987
- HRMY 2017
- Country
- LGND United States
- HRMY United States
- Employees
- LGND N/A
- HRMY N/A
- Industry
- LGND Biotechnology: Pharmaceutical Preparations
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- LGND Health Care
- HRMY Health Care
- Exchange
- LGND Nasdaq
- HRMY Nasdaq
- Market Cap
- LGND N/A
- HRMY 2.0B
- IPO Year
- LGND 1992
- HRMY 2020
- Fundamental
- Price
- LGND $107.62
- HRMY $33.19
- Analyst Decision
- LGND Strong Buy
- HRMY Strong Buy
- Analyst Count
- LGND 6
- HRMY 8
- Target Price
- LGND $145.00
- HRMY $54.00
- AVG Volume (30 Days)
- LGND 135.2K
- HRMY 692.3K
- Earning Date
- LGND 05-06-2025
- HRMY 04-29-2025
- Dividend Yield
- LGND N/A
- HRMY N/A
- EPS Growth
- LGND N/A
- HRMY 17.84
- EPS
- LGND N/A
- HRMY 2.51
- Revenue
- LGND $167,133,000.00
- HRMY $714,734,000.00
- Revenue This Year
- LGND $16.90
- HRMY $20.92
- Revenue Next Year
- LGND $18.27
- HRMY $18.83
- P/E Ratio
- LGND N/A
- HRMY $13.22
- Revenue Growth
- LGND 27.28
- HRMY 22.80
- 52 Week Low
- LGND $67.72
- HRMY $28.14
- 52 Week High
- LGND $129.90
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- LGND 44.36
- HRMY 43.39
- Support Level
- LGND $106.79
- HRMY $32.85
- Resistance Level
- LGND $112.49
- HRMY $33.77
- Average True Range (ATR)
- LGND 4.58
- HRMY 1.21
- MACD
- LGND 0.12
- HRMY 0.03
- Stochastic Oscillator
- LGND 43.87
- HRMY 28.66
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.